New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 25, 2014
07:57 EDTAGNAllergan says CHMP recommends extending OZURDEX marketing authorization
Allergan announced that the European Unionís Committee for Medicinal Products for Human Use, or CHMP, has recommended extending the marketing authorization for OZURDEX to treat adult patients with vision loss due to diabetic macular edema who are pseudophakic, or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy. The CHMP is the scientific committee of the European Medicines Agency that recommends medicines for marketing authorization across the 28 member states of the EU. The final decision from the European Commission is expected within a few months.
News For AGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
17:34 EDTAGNActavis registration statement for Allergan acquisition declared effective
Subscribe for More Information
January 21, 2015
12:30 EDTAGNGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
07:22 EDTAGNActavis price target raised to $330 from $280 at Deutsche Bank
Subscribe for More Information
January 13, 2015
14:00 EDTAGNActavis says Allergan deal could close as early as Q1, as late as Q2
Subscribe for More Information
07:39 EDTAGNAmerican Academy of Cosmetic Surgery to hold a meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use